Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex

Abstract Question: Is add-on cannabidiol superior to placebo in reducing the number of seizures associated with tuberous sclerosis complex? Findings: In this randomized clinical trial, 224 patients with tuberous sclerosis complex were treated with cannabidiol (25 or 50 mg/kg/day) or matched placebo for 16 weeks. The percentage reduction in the type of seizures regarded as the primary end point was 27% for placebo, 49% for 25 mg/kg/day of cannabidiol, and 48% for 50 mg/kg/day of cannabidiol; a dosage of 25